Navigation Links
DrugRisk Center Adds Latest on First of 3,000 Actos Bladder Cancer Trials
Date:3/28/2013

New York, NY (PRWEB) March 28, 2013

The prescription drug resource center DrugRisk.com is announcing new information to the site for those who have taken the medication Actos for diabetes. With drug maker Takeda facing claims from patients alleging bladder cancer, the first trial is underway in California.

The goal of DrugRisk is to improve the safety of patients taking popular prescription drugs by providing the most up-to-date warnings, recalls, studies and legal news. Visitors can determine if others have experienced similar side effects and decide if they need legal advice.

The resource center contains warnings from experts such as the FDA and European Medicines Agency*, who have warned that long-term use of Actos may be associated with an increased bladder cancer risk. The drug has also been banned in France and Germany**.

Although Actos remains on the market in the United States, DrugRisk has learned that as many as 3,000 patients have filed an Actos lawsuit against drug maker Takeda Pharmaceuticals alleging they developed bladder cancer***. Over 1,200 of these have been consolidated in a special multi-district federal court in Louisiana, while others are pending in California.

The resource center has added information from the first of these Actos lawsuit trials, which began this month in California for a retired man dying of bladder cancer***. A former pharmacologist for Takeda testified that, as news of bladder cancer risks spread, executives were more concerned with maintaining sales than the safety of patients***.

Anyone affected by bladder cancer after taking Actos is urged to contact DrugRisk or speak with a lawyer about their legal rights as soon as possible. Lawyers are still helping those affected file claims.

Due to the specialized nature of drug injury litigation, however, DrugRisk only recommends lawyers and law firms who have already handled

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
2. DrugRisk Announces Alternative to Mirena IUD May Be Available Soon
3. DrugRisk Announces Updated Information on Mirena Lawsuits
4. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
5. DrugRisk Announces New Pradaxa Health Warning From Australia
6. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
7. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
8. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
9. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
10. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
11. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/25/2014)... The click strand woven bamboo ... durability. Today, the business announces a click strand ... Jan. 30, 2015. , Click strand woven bamboo ... is a well-known brand in the bamboo industry. ... a reliable bamboo flooring supplier. , “We are ...
(Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
(Date:12/25/2014)... Hills, California (PRWEB) December 25, 2014 ... her home in Woodland Hills, California after an 8 ... passed away on Christmas Eve evening in her home ... with aggressive metastatic breast cancer. , ... for over forty years, she pioneered and championed many ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... , , , , ... of the 32 filed cases around the country have filed a joint ... to Chief Judge James G. Carr of the United States District Court ... July 24, 2009, before the Judicial Panel on Multidistrict Litigation in Washington, ...
... MONICA, Calif., July 24 The following advisory was issued by Consumer Watchdog: , , ... health insurance , , When : , ... , Hilton , Civil Justice Foundation Breakfast of Champions , ... San Francisco, CA 94102 , , What : , ...
... , , WASHINGTON, July 24 ... Department of Veterans Affairs (VA) medical centers, attained over one billion ... , , "Using this technology, ... database, allowing VA physicians immediate access to patient records regardless of ...
... The Hispanic got milk? Milk Mustache,Mobile Tour visited New York as ... to reintroduce Hispanics to this nutrient powerhouse and its,array of benefits. ... local residents not only to live well, but to drink well,with ... the events, Hispanic mothers were given the opportunity to enter the,Milk ...
... Medicine finds suggestive but limited evidence that exposure to Agent ... associated with an increased chance of developing ischemic heart disease ... the latest in a congressionally mandated series by the IOM ... effects of these herbicides and a type of dioxin -- ...
... , , OKLAHOMA CITY, July ... continues to see job opportunities for qualified professionals in the Oklahoma City, ... 6%, Adecco USA currently has demand for 100 pharmacy technicians in the ... , , Over the past year the ...
Cached Medicine News:Health News:Motion Filed to Consolidate Yasmin/YAZ Litigation in Toledo, Ohio 2Health News:CIGNA Whistleblower Calls for More Heath Insurance Accountability in Heath Care Reform 2Health News:VA Medical Imaging Reaches Record Level 2Health News:The Hispanic got milk? Campaign Visited New York July 18 - July 22 2Health News:Limited data suggest possible association between Agent Orange exposure 2Health News:Limited data suggest possible association between Agent Orange exposure 3Health News:Wanted: Oklahoma City Licensed Pharmacy Technicians 2
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... 2011 Reportlinker.com announces that ... is available in its catalogue: ... Drug Safety Strategies and Risk ... clinical success ...
... FRANCISCO, Calif., Oct. 26, 2011 Onyx Pharmaceuticals, ... results from a Bayer HealthCare Pharmaceuticals Phase 3 ... for the treatment of patients with metastatic colorectal ... standard therapies. The trial met its primary endpoint ...
Cached Medicine Technology:Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 2Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 3Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 4Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 5
For use with catalog #0540....
Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Latex Agglutination Slide Test for the Qualitative and Semi-Quantitative Determination of D-Dimer in plasma, 60 tests....
Medicine Products: